Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates ContraFect (CFRX) at Overweight with $15 PT, Expects Upwards Earnings Revisions
-
Cantor Fitzgerald Reiterates Aspira Women’s Health (AWH) at Overweight with $4 PT, Sees Shares as "Materially Undervalued"
-
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
-
Exela Technologies (XELA) PT Lowered to $2 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Aytu Biosciences (AYTU) at Overweight, $11 PT, Sees it as Positive Development Potentially Extending ADHD Franchise Revenue Runway
-
Cantor Fitzgerald Reiterates Overweight Rating on Lucid Diagnostics Inc (LUCD), Sees Launch in Three New Areas as Favorable and as an Important Commercialization Milestone
-
Cantor Fitzgerald Reiterates Pfizer (PFE) at Overweight Rating with $75 PT on Phase 3 etrasimod Data
-
Exagen (XGN) PT Lowered to $19 at Cantor Fitzgerald on Weaker Guidance, but Analyst Maintained Overweight Rating and Positive Outlook, "Would Encourage Investors to Acquire Shares" at Current Valuatio
-
MariMed to Participate in April Investor Conferences
-
Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit
-
Options mavens see stock rebound as chance to pick up downside protection
-
Lanvin Group, a Global Luxury Fashion Group, to Become Publicly Traded on the NYSE via Business Combination with Primavera Capital Acquisition Corporation
-
Applied Genetic Technologies (AGTC) Prices 7.5M Share Offering at $1.31/sh
-
AGTC Announces Pricing of Public Offering of Common Stock
-
AGTC Announces Pricing of Public Offering of Common Stock
-
Reigo Doubles Securitization to $200 Million in Residential Bridge Loans
-
Troika Media (TRKA) Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Aytu BioPharma to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Troika Media Group Completes Transformative Acquisition of Converge Direct LLC Adding Approximately $300 Million of Revenue and $21 Million of Net Income
-
Decibel Therapeutics to Participate in Upcoming Investor Conferences
-
Decibel Therapeutics to Participate in Upcoming Investor Conferences
-
Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit
-
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
-
Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
-
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
-
MannKind Corporation to Participate in the Cantor Virtual Rare Orphan Disease Summit
-
AVINO CLOSES ACQUISITION OF LA PRECIOSA FROM COEUR MINING
-
Applied Genetic Technologies (AGTC) Announces Proposed Stock Offering, Size not Disclosed
-
Applied Genetic Technologies (AGTC) to Offer Common Stock
-
MicroVision's Leaders to Participate in Webcast Fireside Chat with Cantor Fitzgerald Analyst on March 22, 2022
-
AGTC Announces Proposed Public Offering of Common Stock
-
AGTC Announces Proposed Public Offering of Common Stock
-
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
-
HTG Molecular Diagnostics (HTGM) Announces 3.24M Unit Private Placement at $2.31/unit
-
HTG Molecular Diagnostics Announces $7.5 Million Private Placement
-
High Tide Inc. (HITI:CN) (HITI) PT Lowered to Cdn$7 at Cantor Fitzgerald
-
NRx Pharmaceuticals (NRXP) Appoints Ira Strassberg as CFO
-
NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer
-
Form 424B3 Cantor Fitzgerald Income
-
Tempo Automation Secures Up To $100M in Committed Equity Financing
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) Overwight, $10 PT, Sees Company's Bromodomain and Extra-Terminal Domain Inhibitors Programs are Underappreciated
-
TerrAscend Corp. (TRSSF) PT Raised to $7.90 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates eFFECTOR Therapeutics (EFTR) at Overweight, $50 PT, "Company's Pipeline Remains Underappreciated", Expect Advancements to Move Stock Higher
-
Orchid Island Capital Announces March 2022 Monthly Dividend, and February 28, 2022 Rmbs Portfolio Characteristics
-
Form 8-K Cantor Fitzgerald Income For: Mar 11
-
SILVERSTEIN PROPERTIES, CANTOR FITZGERALD AND UNIVERSITY PLACE ASSOCIATES CELEBRATE TOPPING OUT OF LIFE SCIENCE BUILDING IN UNIVERSITY CITY, PHILADELPHIA

